Payment overview · 2025
General Payments
$211.65
10 reported records · 5 companies
Healthcare provider profile · identity verified
Billie Bartley, PAC
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · PIKEVILLE, KY · NPI 1184688855
Verified facts
What the public records show
CMS Open Payments records show Billie Bartley, PAC received $211.65 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 39.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.49 | 39.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.91 | 20.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.70 | 20.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.09 | 12.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.46 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $211.65 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.49 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.49 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 107 |
| Omeprazole | Omeprazole | 278 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 58 |
| Lisinopril | Lisinopril | 243 | 72 |
| Losartan Potassium | Losartan Potassium | 207 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 60 |
| Metformin Hcl | Metformin Hcl | 189 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 188 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 49 |
| Buspirone Hcl | Buspirone Hcl | 182 | 52 |
| Simvastatin | Simvastatin | 179 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 43 |
| Meloxicam | Meloxicam | 160 | 43 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 142 | 38 |
| Montelukast Sodium | Montelukast Sodium | 141 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 135 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 24 |
| Potassium Chloride | Potassium Chloride | 118 | 38 |
| Amoxicillin | Amoxicillin | 112 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 27 |
| Azithromycin | Azithromycin | 96 | 89 |
| Carvedilol | Carvedilol | 91 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 16 |
| Sertraline Hcl | Sertraline Hcl | 86 | 19 |
| Bupropion Xl | Bupropion Hcl | 81 | 17 |
| Telmisartan | Telmisartan | 80 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 13 |
| Methylprednisolone | Methylprednisolone | 66 | 52 |
| Trazodone Hcl | Trazodone Hcl | 64 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 22 |
| Ibuprofen | Ibuprofen | 61 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 35 |
| Mounjaro | Tirzepatide | 57 | 11 |
| Famotidine | Famotidine | 56 | 16 |
| Furosemide | Furosemide | 55 | 20 |
| Glyburide | Glyburide | 50 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 14 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Naproxen | Naproxen | 45 | 11 |
| Ozempic | Semaglutide | 45 | 13 |
| Prednisone | Prednisone | 45 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 15 |
| Glipizide | Glipizide | 41 | 12 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Cefdinir | Cefdinir | 37 | 33 |
| Eliquis | Apixaban | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 17 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 20 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Irbesartan | Irbesartan | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $211.65 · 10 records | ABBVIE INC. | CAPLYTA, Dexcom G6 Transmitter, NURTEC ODT, QULIPTA, UBRELVY, Wegovy, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error